VELICEPT THERAPEUTICS
Velicept Therapeutics, Inc. is a privately held, clinical development company focused on advancing best-in-class compounds with the potential to fill unmet medical needs. Its lead program, solabegron, is a highly differentiated novel compound being investigated for overactive bladder (OAB) and irritable bowel syndrome (IBS). Velicept is a portfolio company of NeXeption. For more information,
VELICEPT THERAPEUTICS
Industry:
Biotechnology Health Care Medical Therapeutics
Founded:
2015-01-01
Address:
Malvern, Pennsylvania, United States
Country:
United States
Website Url:
http://www.velicept.com
Total Employee:
1+
Status:
Closed
Contact:
(484)318-2988
Total Funding:
42 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Domain Not Resolving Apache Mobile Non Scaleable Content Microsoft Exchange Online Amazon Office 365 Mail Microsoft Azure DNS
Current Advisors List
Current Employees Featured
Founder
Investors List
Longitude Capital
Longitude Capital investment in Series B - Velicept Therapeutics
Fountain Healthcare Partners
Fountain Healthcare Partners investment in Series B - Velicept Therapeutics
CDK Associates
CDK Associates investment in Series B - Velicept Therapeutics
Becker Ventures
Becker Ventures investment in Series B - Velicept Therapeutics
Samsara BioCapital
Samsara BioCapital investment in Series B - Velicept Therapeutics
Longitude Capital
Longitude Capital investment in Series B - Velicept Therapeutics
Official Site Inspections
http://www.velicept.com
- Host name: a904c694c05102f30.awsglobalaccelerator.com
- IP address: 13.248.169.48
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
